+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Molecular Diagnostics in Pharmacogenomics Market Size, Share & Trends Analysis Report by Product (Kits & Assays, Reagents, Services), by Therapeutic Area, by Technology, by Region, and Segment Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • August 2025
  • Region: Global
  • Grand View Research
  • ID: 6168304
Description Jump to:
The global molecular diagnostics in pharmacogenomics market size was estimated at USD 699.7 million in 2024 and is projected to reach USD 1.25 billion in 2033, growing at a CAGR of 6.84% from 2025 to 2033. This market focuses on rapid and precise genetic testing that enables tailored drug therapy, improving clinical outcomes and reducing adverse drug reactions.

Molecular diagnostics play a central role in identifying patient-specific genetic variations and are widely adopted in areas such as oncology, cardiovascular conditions, infectious diseases, and neurological disorders. Product offerings within the market span across kits, reagents, and specialized testing services, each addressing different stages of pharmacogenomic workflows. Kits and reagents are widely used in clinical laboratories and research institutions for routine and specialized assays. Services are expanding in relevance due to the need for comprehensive interpretation, bioinformatics support, and regulatory-compliant testing. The oncology segment dominates the therapeutic landscape, with lung, breast, and colorectal cancers accounting for significant test volumes, while emerging interest is observed in neurological and immunological disorders.

In terms of technology, polymerase chain reaction (PCR) remains the most widely used method due to its cost-effectiveness and speed. Sequencing technologies, particularly next-generation sequencing (NGS), are gaining ground for their ability to analyze multiple genes simultaneously. Microarrays and other methods like electrophoresis and nucleic acid amplification techniques also contribute to the testing ecosystem. Continuous innovation, along with rising awareness of gene-drug interactions and expanding access to genomic services globally, is expected to reinforce the growth of this market over the forecast period.

Moreover, at AAN’s Annual Meeting in April 2025, leading neurologists underscored the emergent role of pharmacogenomics in neurology. By focusing on genetic drivers across diseases like Alzheimer’s, Parkinson’s, stroke, migraine, and multiple sclerosis, experts envisioned a paradigm shift toward genetically guided treatment selection, with the potential to enhance efficacy and reduce adverse events. These insights point to a growing clinical demand for PGx-enabled molecular diagnostics in neurological care a development reflecting the broader trend of sequencing-based precision diagnostics being adopted beyond traditional therapeutic boundaries.

Overall, the innovation landscape in the molecular diagnostics in pharmacogenomics industry reflects a shift toward faster, more accessible, and clinically actionable testing solutions. The integration of advanced technologies such as AI, point-of-care systems, and multi-omics platforms is expanding the utility of PGx diagnostics beyond traditional hospital settings, supporting broader adoption across diverse therapeutic areas.

Global Molecular Diagnostics In Pharmacogenomics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the global molecular diagnostics in pharmacogenomics market report based on the product, therapeutic area, technology, and region:

Product Outlook (Revenue, USD Million, 2021-2033)

  • Kits and assays
  • Reagents
  • Services

Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)

  • Oncology
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Technology Outlook (Revenue, USD Million, 2021-2033)

  • PCR
  • Microarray
  • Sequencing
  • Others

Regional Outlook (Revenue, USD Million, 2021-2030)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Rising Demand for Personalized Medicine
3.4.2. Integration of NGS-Based Diagnostics in Clinical Workflows
3.4.3. Expanding Regulatory Support and Reimbursement Frameworks
3.5. Market Restraint Analysis
3.5.1. Limited Awareness Among Healthcare Providers and Patients
3.5.2. Cost-Related Challenges and Reimbursement Variability
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; by Factor (Political & Legal, Economic, and Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Molecular Diagnostics in Pharmacogenomics Market: Product Movement Analysis
4.2. Kits and Assays
4.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
4.3. Reagents
4.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
4.4. Services
4.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Therapeutic Area Business Analysis
5.1. Molecular Diagnostics in Pharmacogenomics Market: Therapeutic Area Movement Analysis
5.2. Oncology
5.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.2.2. Lung Cancer
5.2.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.2.3. Breast Cancer
5.2.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.2.4. Colorectal Cancer
5.2.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.2.5. Cervical Cancer
5.2.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.2.6. Others
5.2.6.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.3. Neurological Disorders
5.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.4. Cardiovascular Disease
5.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Immunological Disorders
5.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.6. Infectious Diseases
5.6.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.7. Others
5.7.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Technology Business Analysis
6.1. Molecular Diagnostics in Pharmacogenomics Market: Technology Movement Analysis
6.2. PCR
6.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.3. Microarray
6.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.4. Sequencing
6.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Others
6.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Molecular Diagnostics in Pharmacogenomics Market Share, by Region, 2023 & 2030
7.2. North America
7.2.1. North America Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Competitive Scenario
7.2.2.4. Regulatory Framework
7.2.2.5. Reimbursement Scenario
7.2.2.6. U.S. Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. Canada Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.2.4. Mexico
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.2.4.6. Mexico Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3. Europe
7.3.1. Europe Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3.2. Germany
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. Reimbursement Scenario
7.3.2.6. Germany Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. UK Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. France Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. Italy Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Spain Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Denmark Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Sweden Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Norway Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.4. Asia-Pacific
7.4.1. Asia-Pacific Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Reimbursement Scenario
7.4.2.6. Japan Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. China Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. India Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.4.5. South Korea
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. South Korea Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.4.6. Australia
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. Australia Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Thailand Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.5. Latin America
7.5.1. Latin America Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Competitive Scenario
7.5.2.4. Regulatory Framework
7.5.2.5. Reimbursement Scenario
7.5.2.6. Brazil Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.5.3. Argentina
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Argentina Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.6. MEA
7.6.1. MEA Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Competitive Scenario
7.6.2.4. Regulatory Framework
7.6.2.5. Reimbursement Scenario
7.6.2.6. South Africa Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. UAE Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. Kuwait Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant’s Overview
8.2. Financial Performance
8.3. Participant Categorization
8.3.1. Market Leaders
8.3.2. Molecular Diagnostics in Pharmacogenomics Market Share Analysis, 2023
8.3.3. Company Profiles
8.3.3.1. Roche Diagnostics
8.3.3.1.1. Company Overview
8.3.3.1.2. Financial Performance
8.3.3.1.3. Product Benchmarking
8.3.3.1.4. Strategic Initiatives
8.3.3.2. QIAGEN
8.3.3.2.1. Company Overview
8.3.3.2.2. Financial Performance
8.3.3.2.3. Product Benchmarking
8.3.3.2.4. Strategic Initiatives
8.3.3.3. Thermo Fisher Scientific
8.3.3.3.1. Company Overview
8.3.3.3.2. Financial Performance
8.3.3.3.3. Product Benchmarking
8.3.3.3.4. Strategic Initiatives
8.3.3.4. Illumina, Inc.
8.3.3.4.1. Company Overview
8.3.3.4.2. Financial Performance
8.3.3.4.3. Product Benchmarking
8.3.3.4.4. Strategic Initiatives
8.3.3.5. Agilent Technologies
8.3.3.5.1. Company Overview
8.3.3.5.2. Financial Performance
8.3.3.5.3. Product Benchmarking
8.3.3.5.4. Strategic Initiatives
8.3.3.6. Abbott Molecular
8.3.3.6.1. Company Overview
8.3.3.6.2. Financial Performance
8.3.3.6.3. Product Benchmarking
8.3.3.6.4. Strategic Initiatives
8.3.3.7. Genomind
8.3.3.7.1. Company Overview
8.3.3.7.2. Financial Performance
8.3.3.7.3. Product Benchmarking
8.3.3.7.4. Strategic Initiatives
8.3.3.8. OneOme
8.3.3.8.1. Company Overview
8.3.3.8.2. Financial Performance
8.3.3.8.3. Product Benchmarking
8.3.3.8.4. Strategic Initiatives
8.3.3.9. Myriad Genetics
8.3.3.9.1. Company Overview
8.3.3.9.2. Financial Performance
8.3.3.9.3. Product Benchmarking
8.3.3.9.4. Strategic Initiatives
8.3.3.10. Invitae (formerly YouScript)
8.3.3.10.1. Company Overview
8.3.3.10.2. Financial Performance
8.3.3.10.3. Product Benchmarking
8.3.3.10.4. Strategic Initiatives
List of Tables
Table 1 Molecular Diagnostics in Pharmacogenomics Market - Industry Snapshot & Key Buying Criteria, 2021-2033
Table 2 Global Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 3 Global Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 4 Global Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 5 Global Molecular Diagnostics in Pharmacogenomics Market, by region, 2021-2033 (USD Million)
Table 6 Molecular Diagnostics in Pharmacogenomics- Key market driver analysis
Table 7 Molecular Diagnostics in Pharmacogenomics- Key market restraint analysis
Table 8 North America Molecular Diagnostics in Pharmacogenomics Market, by country, 2021-2033 (USD Million)
Table 9 North America Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 10 North America Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 11 North America Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 12 U.S. Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 13 U.S. Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 14 U.S. Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 15 Canada Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 16 Canada Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 17 Canada Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 18 Mexico Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 19 Mexico Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 20 Mexico Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 21 Europe Molecular Diagnostics in Pharmacogenomics Market, by country, 2021-2033 (USD Million)
Table 22 Europe Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 23 Europe Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 24 Europe Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 25 Germany Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 26 Germany Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 27 Germany Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 28 UK Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 29 UK Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 30 UK Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 31 France Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 32 France Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 33 France Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 34 Italy Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 35 Italy Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 36 Italy Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 37 Spain Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 38 Spain Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 39 Spain Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 40 Denmark Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 41 Denmark Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 42 Denmark Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 43 Sweden Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 44 Sweden Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 45 Sweden Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 46 Norway Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 47 Norway Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 48 Norway Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 49 Asia-Pacific Molecular Diagnostics in Pharmacogenomics Market, by country, 2021-2033 (USD Million)
Table 50 Asia-Pacific Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 51 Asia-Pacific Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 52 Asia-Pacific Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 53 Japan Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 54 Japan Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 55 Japan Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 56 China Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 57 China Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 58 China Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 59 India Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 60 India Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 61 India Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 62 Australia Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 63 Australia Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 64 Australia Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 65 South Korea Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 66 South Korea Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 67 South Korea Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 68 Thailand Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 69 Thailand Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 70 Thailand Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 71 Latin America Molecular Diagnostics in Pharmacogenomics Market, by country, 2021-2033 (USD Million)
Table 72 Latin America Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 73 Latin America Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 74 Latin America Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 75 Brazil Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 76 Brazil Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 77 Brazil Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 78 Argentina Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 79 Argentina Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 80 Argentina Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 81 MEA Molecular Diagnostics in Pharmacogenomics Market, by country, 2021-2033 (USD Million)
Table 82 MEA Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 83 MEA Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 84 MEA Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 85 South Africa Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 86 South Africa Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 87 South Africa Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 88 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 89 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 90 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 91 UAE Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 92 UAE Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 93 UAE Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
Table 94 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by product, 2021-2033 (USD Million)
Table 95 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021-2033 (USD Million)
Table 96 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by Therapeutic Area
List of Figures
Figure 1 Molecular Diagnostics in Pharmacogenomics Market Segmentation
Figure 2 Global Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 3 Molecular Diagnostics in Pharmacogenomics Market Dynamics
Figure 4 Key Opportunities Prioritized, 2021
Figure 5 Molecular Diagnostics in Pharmacogenomics Market - Porter’s Analysis
Figure 6 Molecular Diagnostics in Pharmacogenomics Market - PESTEL Analysis
Figure 7 Molecular Diagnostics in Pharmacogenomics Revenue Share, by Product, 2023 & 2030
Figure 8 Kits and assays Market, 2021-2033 (USD Million)
Figure 9 Reagents Market, 2021-2033 (USD Million)
Figure 10 Services Market, 2021-2033 (USD Million)
Figure 11 Molecular Diagnostics in Pharmacogenomics Revenue Share, by Technology, 2023 & 2030
Figure 12 PCR Market, 2021-2033 (USD Million)
Figure 13 Microarray Market, 2021-2033 (USD Million)
Figure 14 Sequencing Market, 2021-2033 (USD Million)
Figure 15 Others Market, 2021-2033 (USD Million)
Figure 16 Molecular Diagnostics in Pharmacogenomics Revenue Share, by Therapeutic Area, 2023 & 2030
Figure 17 Oncology Market, 2021-2033 (USD Million)
Figure 18 Lung Cancer Market, 2021-2033 (USD Million)
Figure 19 Breast Cancer Market, 2021-2033 (USD Million)
Figure 20 Colorectal Cancer Market, 2021-2033 (USD Million)
Figure 21 Cervical Cancer Market, 2021-2033 (USD Million)
Figure 22 Others Market, 2021-2033 (USD Million)
Figure 23 Neurological Disorders Market, 2021-2033 (USD Million)
Figure 24 Cardiovascular Disease Market, 2021-2033 (USD Million)
Figure 25 Immunological Disorders Market, 2021-2033 (USD Million)
Figure 26 Infectious Diseases Market, 2021-2033 (USD Million)
Figure 27 Others Market, 2021-2033 (USD Million)
Figure 28 Molecular Diagnostics in Pharmacogenomics Revenue Share, by Region, 2023 & 2030
Figure 29 North America Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 30 US Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 31 Canada Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 32 Mexico Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 33 Europe Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 34 Germany Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 35 UK Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 36 France Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 37 Italy Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 38 Spain Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 39 Denmark Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 40 Sweden Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 41 Norway Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 42 Asia-Pacific Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 43 Japan Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 44 China Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 45 India Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 46 Australia Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 47 South Korea Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 48 Thailand Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 49 Latin America Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 50 Brazil Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 51 Argentina Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 52 MEA Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 53 South Africa Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 54 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 55 UAE Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)
Figure 56 Kuwait Molecular Diagnostics in Pharmacogenomics Market, 2021-2033 (USD Million)

Companies Mentioned

The major companies profiled in this Molecular Diagnostics in Pharmacogenomics market report include:
  • Roche Diagnostics
  • QIAGEN
  • Thermo Fisher Scientific
  • Illumina, Inc.
  • Agilent Technologies
  • Abbott Molecular
  • Genomind
  • OneOme
  • Myriad Genetics
  • Invitae (formerly YouScript)

Table Information

Report AttributeDetails
No. of Pages150
PublishedAugust 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 699.7 Million
Forecasted Market Value ( USD ) by 2033 $ 1250 Million
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Genetic Testing Market Size, Share, Trends and Forecast by Type, Technology, Application, and Region, 2025-2033 - Product Image

Genetic Testing Market Size, Share, Trends and Forecast by Type, Technology, Application, and Region, 2025-2033

  • Report
  • 144 Pages
  • Global
From
United States Molecular Diagnostics Market Report Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

United States Molecular Diagnostics Market Report Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • United States
From
Global Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Forecast to 2031 - Product Image

Global Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Forecast to 2031

  • Report
  • 210 Pages
  • Global
From
Japan Molecular Diagnostics Market Analysis and Forecast 2025-2033 - Product Image

Japan Molecular Diagnostics Market Analysis and Forecast 2025-2033

  • Report
  • 200 Pages
  • Japan
From
Single Nucleotide Polymorphism Genotyping Market 2025-2033 - Product Image

Single Nucleotide Polymorphism Genotyping Market 2025-2033

  • Report
  • 139 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.